access to medicines

Printer-friendly version
Minister of health makes dubious claims about Ottawa’s pharmacare plan

More regulation will likely lead to slower and more limited access to drugs.

Printer-friendly version
National pharmacare can hurt patients more than it helps

Canadians can also expect tax hikes to pay for the government drug program.

Printer-friendly version
Canada's free ride on U.S. drug development may end soon

In a bid to get even steeper drug discounts, Health Canada recently proposed changes to our reference-pricing system.

Printer-friendly version
Increasing barriers for drug manufacturers may ultimately hurt patients

Ottawa’s changes may delay the launch of new innovative medications in Canada.

Printer-friendly version
Queen's Park should amend existing programs to better target vulnerable groups.

Printer-friendly version

Under Medicare in the U.S., private insurers compete to offer coverage within regions.

Printer-friendly version

National Pharmacare appears to be regarded by many as a panacea for the woes of the present hodgepodge of provincial drug plans, but some provinces seem to view it as an opportunity to alleviate the strain on their drug budgets.